Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 4/20 | 0.36 |
| ▸ | MMP1 | P03956 | 3/20 | 0.36 |
| ▸ | MMP3 | P08254 | 3/20 | 0.36 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.36 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.36 |
| ▸ | BCL9 | O00512 | 1/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.35 |
| ▸ | REN | P00797 | 5/20 | 0.35 |
| ▸ | MMP7 | P09237 | 2/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.35 |
| ▸ | BMP1 | P13497 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | FABP7 | O15540 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3913491 | 1.00 | MMP9 (0.36) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL3905577 | 0.95 | REN (0.40) | RENPDE4BTMEM97SIGMAR1 | |
| SCHEMBL1036379 | 0.95 | REN (0.39) | RENTMEM97SIGMAR1 | |
| SCHEMBL3267738 | 0.95 | REN (0.35) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL2343571 | 0.94 | MMP9 (0.37) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL2341075 | 0.94 | MMP9 (0.36) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL1081448 | 0.94 | REN (0.36) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL4582330 | 0.93 | REN (0.36) | RENPDE4BTMEM97SIGMAR1 | |
| SCHEMBL1040324 | 0.93 | MMP9 (0.36) | MMP9MMP1MMP3ADAM17ADAM9 | |
| SCHEMBL2335814 | 0.93 | MMP9 (0.36) | MMP9MMP1MMP3ADAM17ADAM9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776359-B1 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2011-08-24 | — | — | EP | disclosed |
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-27 | — | — | US | disclosed |
| EP-1816122-A2 | 3,4,5-substituted piperidines as therapeutic compounds | Speedel Experimenta AG (CH) | 2007-08-08 | — | — | EP | disclosed |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | SPEEDEL EXPERIMENTA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| EP-1776359-A2 | PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| WO-2006005741-A2 | PIPERDINE DERIVATIVES AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076766-A1 | Piperidine Derivatives As Renin Inhibitor | REN, AGTR1, ACE | MMP9 483/4885MMP1 271/4885MMP3 405/4885 |
| US-20070167433-A1 | 3,4,5-Substituted piperidines as therapeutic compounds | CTSD, CTSL, CTSZ | MMP9 107/4885MMP1 284/4885MMP3 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.